Substrate specificity for normal but not mutationally activated variants of src family kinasesSARTOR, O; ROBBINS, K. C.The Journal of biological chemistry (Print). 1993, Vol 268, Num 28, pp 21014-21020, issn 0021-9258Article

Determination of CAG repeat length in the androgen-receptor gene using frozen serumSARTOR, O; ZHENG, Q.Urology (Ridgewood, NJ). 1997, Vol 49, Num 2, pp 301-304, issn 0090-4295Article

Progressive prostate cancer associated with use of megestrol acetate administered for control of hot flashesSARTOR, O; EASTHAM, J. A.Southern medical journal (Birmingham). 1999, Vol 92, Num 4, pp 415-416, issn 0038-4348Article

Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancerEASTHAM, J. A; SARTOR, O.The Journal of urology. 1998, Vol 159, Num 3, issn 0022-5347, p. 990Article

Analogous tamoxifen and estrogen effects on transforming growth factor-betas 1 and 2 in the rat uterusSATOR, B. M; SARTOR, O; FLANDERS, K. C et al.Reproductive toxicology (Elmsford, NY). 1995, Vol 9, Num 3, pp 225-231, issn 0890-6238Article

Suramin, an experimetnal chemotherapeutic drug, activates the receptor for epidermal growth factor and promotes growth of certain malignant cellsCARDINALI, M; SARTOR, O; ROBBINS, K. C et al.The Journal of clinical investigation. 1992, Vol 89, Num 4, pp 1242-1247, issn 0021-9738Article

Differential association of cellular proteins with family protein-tyrosine kinasesSARTOR, O; SAMESHIMA, J. H; ROBBINS, K. C et al.The Journal of biological chemistry (Print). 1991, Vol 266, Num 10, pp 6462-6466, issn 0021-9258, 5 p.Article

Parallel studies of His-DTrp-Ala-Trp-DPhe-Lys-NH₂ and human pancreatic growth hormone-releasing factor-44-NH₂ in rat primary pituitary cell monolayer cultureSARTOR, O; BOWERS, C. Y; DING CHANG et al.Endocrinology (Philadelphia). 1985, Vol 116, Num 3, pp 952-957, issn 0013-7227Article

Comparison of src-family cDNAs reveals distinct mechanisms underlying focus formation in transfected fibroblastsSARTOR, O; MCLELLAN, C. A; CHIUEH, T et al.The Journal of biological chemistry (Print). 1992, Vol 267, Num 29, pp 21044-21051, issn 0021-9258Article

Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancerSARTOR, O; QIANG ZHENG; EASTHAM, J. A et al.Urology (Ridgewood, NJ). 1999, Vol 53, Num 2, pp 378-380, issn 0090-4295Article

cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression : implication in human prostate cancer bone metastasisWU, D; ZHAU, H. E; HUANG, W.-C et al.Oncogene (Basingstoke). 2007, Vol 26, Num 35, pp 5070-5077, issn 0950-9232, 8 p.Article

A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer : toxicity and responseBOWDEN, C. J; FIGG, W. D; DAWSON, N. A et al.Cancer chemotherapy and pharmacology. 1996, Vol 39, Num 1-2, pp 1-8, issn 0344-5704Article

A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancerFIGG, W. D; THIBAULT, A; COOPER, M. R et al.Cancer. 1995, Vol 75, Num 8, pp 2159-2164, issn 0008-543XArticle

Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of hormone-refractory prostate cancerSARTOR, O; COOPER, M; WEINBERGER, M et al.Journal of the National Cancer Institute. 1994, Vol 86, Num 3, pp 222-227, issn 0027-8874Article

Race is not independently associated with a positive prostate biopsy in men suspected of having prostate cancerKUBRICHT, W. S; KATTAN, M. W; SARTOR, O et al.Urology (Ridgewood, NJ). 1999, Vol 53, Num 3, pp 553-556, issn 0090-4295Article

Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancerSARTOR, O; WEINBERGER, M; MOORE, A et al.Urology (Ridgewood, NJ). 1998, Vol 52, Num 2, pp 252-256, issn 0090-4295Article

Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinomaFIGG, W. D; KROOG, G; DURAY, P et al.Cancer. 1997, Vol 79, Num 10, pp 1964-1968, issn 0008-543XArticle

Antigrowth factor strategiesMYERS, C; TREPEL, J; SARTOR, O et al.Cancer. 1993, Vol 71, Num 3, pp 1172-1178, issn 0008-543X, SUPConference Paper

Variables determining the growth hormone response of His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ in the ratSARTOR, O; BOWERS, C. Y; REYNOLDS, G. A et al.Endocrinology (Philadelphia). 1985, Vol 117, Num 4, pp 1441-1447, issn 0013-7227Article

A phase II study of bromocriptine in patients with androgen-independent prostate cancerHORTI, J; FIGG, W. D; WEINBERGER, B et al.Oncology reports. 1998, Vol 5, Num 4, pp 893-896, issn 1021-335XArticle

Influence of hepatic function on serum levels of prostate specific antigenWILLIAMS, P. B; EASTHAM, J. A; CULKIN, D. J et al.The Journal of urology. 1997, Vol 158, Num 5, pp 1867-1869, issn 0022-5347Article

Acute renal toxicity associated with suramin in the treatment of prostate cancerFIGG, W. D; COOPER, M. R; THIBAULT, A et al.Cancer. 1994, Vol 74, Num 5, pp 1612-1614, issn 0008-543XArticle

Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/mLEASTHAM, J. A; MAY, R; ROBERTSON, J. L et al.Urology (Ridgewood, NJ). 1999, Vol 54, Num 4, pp 709-713, issn 0090-4295Article

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer : Recommendations from the prostate-specific antigen working groupBUBLEY, G. J; CARDUCCI, M; HUSSAIN, M et al.Journal of clinical oncology. 1999, Vol 17, Num 11, pp 3461-3467, issn 0732-183XArticle

A phase I study of pentosan polysulfate sodium in patients with advanced malignanciesLUSH, R. M; FIGG, W. D; PLUDA, J. M et al.Annals of oncology. 1996, Vol 7, Num 9, pp 939-944, issn 0923-7534Article